In our previous work [12], DEL-22379 was characterized as an ERK2 dimerization inhibitor, presenting the capacity to inhibit cell growth in RAS-ERK pathway-mutant tumor cells, without affecting ERK2 phosphorylation. Here, MAPK1 is linked to neoplasm.